FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

S Barni

Research Profile

Chemicals & Drugs

Disorders

Procedures

Anatomy

Concepts & Ideas

Leukocyte Count

Co-author Network

Publications

TOP 3
Veronica Bordin; Luisa Giani; S Meregalli; Roberta Bukovec; MM Vaghi; Mario Mandalà; F Paolorossi; Antonio Ardizzoia; Gabriele Tancini; S Barni; F Frigerio; Luca Fumagalli; A Bordoni; G Valsuani; G Di Felice; Paolo Lissoni
Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients.
Mario Mandalà; Paolo Lissoni; Antonio Ardizzoia; S Barni; Franco Rovelli; G Confalonieri; Fabio Malugani; C Moro; Gabriele Fumagalli; Luisa Giani; Gabriele Tancini
Endocrinological study of the dopaminergic regulation of prolactin release in metastatic breast cancer.
Paolo Lissoni; S Barni; Mario Mandalà; Antonio Ardizzoia; F Paolorossi; MM Vaghi; R Longarini; Fabio Malugani; Gabriele Tancini
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of S Barni (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2000: Veronica Bordin; Luisa Giani; S Meregalli; Roberta Bukovec; MM Vaghi; Mario Mandalà; F Paolorossi; Antonio Ardizzoia; Gabriele Tancini; S Barni; F Frigerio; Luca Fumagalli; A Bordoni; G Valsuani; G Di Felice; Paolo Lissoni
Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients.
Urologia internationalis 2000;64(1):3-8.
1999: Mario Mandalà; Paolo Lissoni; Antonio Ardizzoia; S Barni; Franco Rovelli; G Confalonieri; Fabio Malugani; C Moro; Gabriele Fumagalli; Luisa Giani; Gabriele Tancini
Endocrinological study of the dopaminergic regulation of prolactin release in metastatic breast cancer.
Tumori 1999;85(6):494-7.
1999: Paolo Lissoni; S Barni; Mario Mandalà; Antonio Ardizzoia; F Paolorossi; MM Vaghi; R Longarini; Fabio Malugani; Gabriele Tancini
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.
European journal of cancer (Oxford, England : 1990) 1999;35(12):1688-92.
1999: Paolo Lissoni; L Vigore; R Ferranti; Roberta Bukovec; S Meregalli; mario mandala; S Barni; Gabriele Tancini; Luca Fumagalli; Luisa Giani
Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease.
Journal of biological regulators and homeostatic agents 1999;13(4):216-9.
1999: Paolo Lissoni; S Bolis; Mario Mandalà; Simonetta Viviani; E Pogliani; S Barni
Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2.
The International journal of biological markers 1999;14(3):167-71.
1999: Paolo Lissoni; Gabriele Tancini; F Paolorossi; Mario Mandalà; Antonio Ardizzoia; Fabio Malugani; Luisa Giani; S Barni
Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study.
Journal of pineal research 1999;26(3):169-73.
1999: Paolo Lissoni; Franco Rovelli; S Pittalis; M Casati; Luisa Giani; S Barni; Luca Fumagalli; Moshe Laudon
[Therapy with melatonin does not suppress its endogenous production in healthy volunteers].
Recenti progressi in medicina 1999;90(2):84-5.
1998: Paolo Lissoni; Franco Rovelli; Mario Mandalà; S Barni
Blood concentrations of interleukin-15 in cancer patients and their variations during interleukin-2 immunotherapy: preliminary considerations.
The International journal of biological markers 1998;13(3):169-71.
1998: Paolo Lissoni; Franco Rovelli; Luisa Giani; mario mandala; S Meregalli; S Barni; G Confalonieri; A Bonfanti
Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic disease.
The International journal of biological markers 1998;13(3):154-7.
1998: S Barni; Antonio Ardizzoia
Tamoxifen-induced sexual dysfunction in a breast cancer patient: a case report.
Tumori 1998;84(3):417-8.
1998: Paolo Lissoni; Susan Mengo; Mario Mandalà; E Mauri; Fernando Brivio; Franco Rovelli; G Confalonieri; R Longarini; A Bonfante; D Folli; S Meregalli; S Barni; Gabriele Tancini; Luisa Giani
Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
Journal of biological regulators and homeostatic agents 1998;12(1-2):38-41.
1998: S Barni; Paolo Lissoni; S Meregalli; Antonio Ardizzoia; Susan Mengo; Flavia Musco; D Merlini; Gabriele Tancini
Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Tumori 1998;84(1):45-7.
1997: Paolo Lissoni; Franco Rovelli; M R Rivolta; C Frigerio; Mario Mandalà; S Barni; Antonio Ardizzoia; Fabio Malugani; Gabriele Tancini
Acute endocrine effects of interleukin-12 in cancer patients.
Journal of biological regulators and homeostatic agents 1997;11(4):154-6.
1997: Paolo Lissoni; F Paolorossi; Antonio Ardizzoia; S Barni; M Chilelli; M Mancuso; Gabriele Tancini; Ario Conti; Georges Maestroni
A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state.
Journal of pineal research 1997;23(1):15-9.
1997: Paolo Lissoni; S Barni; G Di Felice; F Majorca; Luca Fumagalli
Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
The International journal of biological markers 1997;12(3):134-6.
1997: Paolo Lissoni; Franco Rovelli; L Fumagalli; E Mauri; S Barni; Gabriele Tancini
Increased blood concentrations of interleukin-12 are associated with a longer survival in untreatable metastatic solid tumor patients: preliminary observations.
The International journal of biological markers 1997;12(3):125-7.
1997: Paolo Lissoni; S Barni; Antonio Ardizzoia; F Paolorossi; Gabriele Tancini; M Andres; Paolo Favini; Epifanio Scardino; Francesco Rocco
[Immunotherapy for metastatic renal carcinoma with interleukin-2 in a subcutanous administration schedule of short duration. Subcutaneous IL-2 in renal carcinoma].
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1997;69(3):159-62.
1997: Paolo Lissoni; Gabriele Tancini; S Barni; F Paolorossi; Antonio Ardizzoia; Ario Conti; Georges Maestroni
Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1997;5(2):126-9.
1997: Paolo Lissoni; S Barni; Gabriele Tancini; M Cazzaniga; F Frigerio; M Chilelli; Epifanio Scardino; M Andres; Paolo Favini; T Meroni; F Verwei; A Baccalin; Maurizio Sala; Bruno Frea; Ervin Kocjancic; Francesco Rocco
[Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Subcutaneous Il-2 in renal carcinoma].
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1997;69(1):41-7.
1997: Paolo Lissoni; M Cazzaniga; S Barni; Maristella Perego; Fernando Brivio; Luca Fumagalli; Gabriele Tancini
Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2.
European journal of cancer (Oxford, England : 1990) 1997;33(2):304-6.
1997: Paolo Lissoni; M Cazzaniga; Gabriele Tancini; Epifanio Scardino; R Musci; S Barni; M Maffezzini; T Meroni; Francesco Rocco; Ario Conti; Georges Maestroni
Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
European urology 1997;31(2):178-81.
1996: Paolo Lissoni; G Tancini; S Barni; F Paolorossi; F Rossini; P Maffé; L Di Bella
The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia.
Recenti progressi in medicina 1996;87(12):582-5.
1996: Paolo Lissoni; O Brivio; Fernando Brivio; S Barni; Gabriele Tancini; D Crippa; S Meregalli
Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma.
Journal of pineal research 1996;21(4):239-42.
1996: Paolo Lissoni; F Paolorossi; Gabriele Tancini; Antonio Ardizzoia; S Barni; Fernando Brivio; G J Maestroni; M Chilelli
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.
British journal of cancer 1996;74(9):1466-8.
1996: G Di Felice; Luca Fumagalli; F Majorca; S Barni; Antonio Ardizzoia; Gabriele Tancini; Paolo Lissoni
Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2.
Journal of biological regulators and homeostatic agents 1996;10(4):98-9.
1996: Paolo Lissoni; F Paolorossi; Gabriele Tancini; S Barni; Antonio Ardizzoia; Fernando Brivio; Barbara Zubelewicz; V Chatikhine
Is there a role for melatonin in the treatment of neoplastic cachexia?
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1340-3.
1996: Paolo Lissoni; S Pittalis; Antonio Ardizzoia; Fernando Brivio; S Barni; Gabriele Tancini; F Pelizzoni; G J Maestroni; Barbara Zubelewicz; Ryszard Braczkowski
Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1996;4(4):313-6.
1996: Fernando Brivio; Paolo Lissoni; G Alderi; S Barni; F Lavorato; Luca Fumagalli
Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.
Oncology 1996;53(4):263-8.
1996: Paolo Lissoni; Fernando Brivio; S Pittalis; Franco Rovelli; R Rescaldani; Maristella Perego; M G Grassi; S Barni; Gabriele Tancini; F Majorca; Luca Fumagalli
Clinical significance of erythrosedimentation rate in cancer in relation to cytokine production: correlation with high IL-6 and low IL-2 blood concentrations.
Journal of biological regulators and homeostatic agents 1996;10(2-3):60-2.
1996: S Barni; R Mondin; R Nazzani; C Archili
Oncostress: evaluation of burnout in Lombardy.
Tumori 1996;82(1):85-92.
1996: Paolo Lissoni; Antonio Ardizzoia; S Barni; S Pittalis; F Rossini; A Porta; Gabriele Tancini
Characterization of cancer-related disseminated intravascular coagulation in relation to tumor necrosis factor-alpha blood concentrations: possible therapeutic role of pentoxifylline.
Tumori 1996;82(1):78-80.
1996: S Barni; Paolo Lissoni; Gabriele Tancini; Antonio Ardizzoia; M Cazzaniga
Effects of one-year adjuvant treatment with tamoxifen on bone mineral density in postmenopausal breast cancer women.
Tumori 1996;82(1):65-7.
1996: Paolo Lissoni; S Meregalli; L Nosetto; S Barni; Gabriele Tancini; V Fossati; G Maestroni
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone.
Oncology 1996;53(1):43-6.
1995: Paolo Lissoni; S Barni; M Cazzaniga; Antonio Ardizzoia; Franco Rovelli; Gabriele Tancini; Fernando Brivio; F Frigerio
Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretion.
Oncology 1995;52(6):439-42.
1995: Paolo Lissoni; L Vigorè; R Rescaldani; Franco Rovelli; Fernando Brivio; Luisa Giani; S Barni; Gabriele Tancini; Antonio Ardizzoia; M G Viganò
Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study.
Journal of biological regulators and homeostatic agents 1995;9(4):155-8.
1995: Paolo Lissoni; Franco Rovelli; E Tisi; Fernando Brivio; Antonio Ardizzoia; S Barni; Gabriele Tancini; M Saudelli; E Cesana; M G Viganò
Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors.
Journal of biological regulators and homeostatic agents 1995;9(4):146-9.
1995: Ryszard Braczkowski; Barbara Zubelewicz; Wojciech Romanowski; Paolo Lissoni; S Barni
Modulation of tumor necrosis factor-alpha (TNF-alpha) toxicity by the pineal hormone melatonin (MLT) in metastatic solid tumor patients.
Annals of the New York Academy of Sciences 1995;768():334-6.
1995: Paolo Lissoni; S Barni; Fernando Brivio; F Rossini; Luca Fumagalli; Antonio Ardizzoia; Gabriele Tancini
A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia.
Oncology 1995;52(5):360-2.
1995: Paolo Lissoni; S Barni; Antonio Ardizzoia; F Frigerio; F Paolorossi; M Cazzaniga; Gabriele Tancini; Francesco Rocco; M Aapro
Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1.
Tumori 1995;81(4):261-4.
1995: S Barni; Paolo Lissoni; M Cazzaniga; Antonio Ardizzoia; S Meregalli; V Fossati; Luca Fumagalli; Fernando Brivio; Gabriele Tancini
A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
Oncology 1995;52(3):243-5.
1995: Paolo Lissoni; S Barni; V Fossati; Antonio Ardizzoia; M Cazzaniga; Gabriele Tancini; F Frigerio
A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1995;3(3):194-7.
1995: Paolo Lissoni; Epifanio Scardino; Paolo Favini; S Barni; Gabriele Tancini; A Baccalin; F Verweij; G Strada; R Musci; Francesco Rocco
[Prognostic predictive factors of the clinical response to immunotherapy with subcutaneous interleukin-2, in patients with metastatic renal carcinoma: analysis of 60 cases].
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1995;67(2):149-53.
1995: M G Viganò; Paolo Lissoni; S Barni; Gabriele Tancini; Epifanio Scardino; Paolo Favini; A Baccalini; F Verweij; G Strada; Francesco Rocco
[Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma].
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1995;67(2):143-7.
1995: Paolo Lissoni; S Barni; S Meregalli; V Fossati; M Cazzaniga; D Esposti; Gabriele Tancini
Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.
British journal of cancer 1995;71(4):854-6.
1995: Paolo Lissoni; S Barni; Gabriele Tancini; E Mainini; F Piglia; G J Maestroni; A Lewinski
Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
Oncology 1995;52(2):163-6.
1995: Paolo Lissoni; S Barni; Antonio Ardizzoia; Epifanio Scardino; Gabriele Tancini; M G Viganò
Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
Journal of biological regulators and homeostatic agents 1995;9(1):21-3.
1995: F Paolorossi; S Villa; S Barni; Gabriele Tancini; M Andres; Paolo Lissoni
Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy.
Tumori 1995;81(1):45-7.
1995: Paolo Lissoni; S Barni; Gabriele Tancini; Antonio Ardizzoia; E Tisi; M Angeli; A Rizzi
Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon alpha, beta and interleukin-2.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1995;3(1):78-80.
1994: Paolo Lissoni; S Meregalli; V Fossati; F Paolorossi; S Barni; Gabriele Tancini; F Frigerio
A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer.
Tumori 1994;80(6):464-7.
1994: Paolo Lissoni; S Barni; Gabriele Tancini; V Fossati; F Frigerio
Pineal-opioid system interactions in the control of immunoinflammatory responses.
Annals of the New York Academy of Sciences 1994;741():191-6.
1994: Paolo Lissoni; S Barni; Gabriele Tancini; Fernando Brivio; E Tisi; Barbara Zubelewicz; Ryszard Braczkowski
Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
Journal of biological regulators and homeostatic agents 1994;8(4):126-9.
1994: Paolo Lissoni; S Barni; M Andres; Epifanio Scardino; L Vigoré; R Vezzo; R Rescaldani; Gabriele Tancini
Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2.
Tumori 1994;80(4):283-5.
1994: S Barni; Antonio Ardizzoia; Giovanni Bernardo; S Villa; Mariarosa Strada; M Cazzaniga; C Archili; L Frontini
Vinorelbine as single agent in pretreated patients with advanced breast cancer.
Tumori 1994;80(4):280-2.
1994: Paolo Lissoni; S Barni; M Cazzaniga; Antonio Ardizzoia; Franco Rovelli; Fernando Brivio; Gabriele Tancini
Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone.
Oncology 1994;51(4):344-7.
1994: R Brackowski; Barbara Zubelewicz; Wojciech Romanowski; Paolo Lissoni; S Barni; Gabriele Tancini; G J Maestroni
Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
Journal of biological regulators and homeostatic agents 1994;8(3):77-80.
1994: S Barni; Paolo Lissoni; Fernando Brivio; Luca Fumagalli; D Merlini; M Cataldo; Franco Rovelli; Gabriele Tancini
Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin.
Tumori 1994;80(3):212-5.
1994: Paolo Lissoni; M Cazzaniga; Franco Rovelli; E Mainini; Gabriele Tancini; S Barni
Ondansetron does not stimulate prolactin release in breast cancer patients.
Tumori 1994;80(3):209-11.
1994: Paolo Lissoni; A Bastone; S Barni; Gabriele Tancini; M A Galli
Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2.
Journal of biological regulators and homeostatic agents 1994;8(2):65-6.
1994: Paolo Lissoni; S Barni; Antonio Ardizzoia; V Fossati; F Paolorossi; Gabriele Tancini
Weekly epirubicin plus low-dose interleukin-2 subcutaneous therapy in breast cancer: preliminary immunobiological results.
Journal of biological regulators and homeostatic agents 1994;8(2):53-5.
1994: Paolo Lissoni; S Barni; Gabriele Tancini; Antonio Ardizzoia; G Ricci; R Aldeghi; Fernando Brivio; E Tisi; Franco Rovelli; R Rescaldani
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
British journal of cancer 1994;69(1):196-9.
1994: Paolo Lissoni; S Barni; Antonio Ardizzoia; S Crispino; F Paolorossi; M Andres; Epifanio Scardino; Gabriele Tancini
Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma.
Oncology 1994;51(1):59-62.
1994: R Aldeghi; Paolo Lissoni; S Barni; Antonio Ardizzoia; Gabriele Tancini; A Piperno; M Pozzi; G Ricci; A Conti; G J Maestroni
Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma.
European journal of cancer (Oxford, England : 1990) 1994;30A(2):167-70.
1994: Paolo Lissoni; Fernando Brivio; Luca Fumagalli; C Galimberti; M Cataldo; M T Marsili; O Brivio; S Barni; Gabriele Tancini; A Angelini
A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors.
Journal of biological regulators and homeostatic agents 1994;8(1):32-5.
1993: Paolo Lissoni; Fernando Brivio; Antonio Ardizzoia; Gabriele Tancini; S Barni
Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status.
Tumori 1993;79(6):401-4.
1993: Paolo Lissoni; S Barni; Antonio Ardizzoia; M Andres; Epifanio Scardino; P Cardellini; R Della Bitta; Gabriele Tancini
A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma.
Tumori 1993;79(6):397-400.
1993: Paolo Lissoni; S Barni; Gabriele Tancini; Franco Rovelli; Antonio Ardizzoia; A Conti; G J Maestroni
A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients.
Oncology 1993;50(6):399-402.
1993: Antonio Ardizzoia; Paolo Lissoni; Gabriele Tancini; F Paolorossi; S Crispino; S Villa; S Barni
Respiratory distress syndrome in patients with advanced cancer treated with pentoxifylline: a randomized study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1993;1(6):331-3.
1993: S Barni; Paolo Lissoni; A Ardizzola; L Vigoré; R Vezzo; R Rescaldani; Gabriele Tancini
Immunotherapy with low-dose subcutaneous interleukin-2 plus beta-interferon as a second-line therapy for metastatic colorectal carcinoma.
Tumori 1993;79(5):343-6.
1993: Paolo Lissoni; S Barni; Antonio Ardizzoia; G Olivini; Fernando Brivio; E Tisi; Gabriele Tancini; D Characiejus; L Kothari
Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
Journal of biological regulators and homeostatic agents 1993;7(4):121-5.
1993: Paolo Lissoni; S Barni; Gabriele Tancini; Fernando Brivio; P Cardellini; M Vaghi; V Fossati; F Frigerio
Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapy.
Tumori 1993;79(4):246-9.
1993: S Crispino; Paolo Lissoni; Antonio Ardizzoia; Franco Rovelli; Maristella Perego; M G Grassi; S Barni; S Pittalis; Gabriele Tancini
Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
Journal of biological regulators and homeostatic agents 1993;7(3):92-4.
1993: Paolo Lissoni; M A Galli; Gabriele Tancini; S Barni
Prevention by L-carnitine of interleukin-2 related cardiac toxicity during cancer immunotherapy.
Tumori 1993;79(3):202-4.
1993: Paolo Lissoni; S Meregalli; V Fossati; S Barni; Gabriele Tancini; P Barigozzi; F Frigerio
Radioendocrine therapy of brain tumors with the long acting opioid antagonist naltrexone in association with radiotherapy.
Tumori 1993;79(3):198-201.
1993: Paolo Lissoni; S Barni; Gabriele Tancini; Antonio Ardizzoia; Franco Rovelli; M Cazzaniga; Fernando Brivio; A Piperno; R Aldeghi; D Fossati
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
British journal of cancer 1993;67(6):1404-7.
1993: Paolo Lissoni; S Barni; Gabriele Tancini; M Andres; Epifanio Scardino; P Cardellini; M Frascaroli; Antonio Ardizzoia; S Crispino; D Vicini
[Immunotherapy with low-dose subcutaneous interleukin-2 in metastatic renal carcinoma].
Archivio italiano di urologia, andrologia : organo ufficiale [di] Società italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 1993;65(2):123-8.
1993: Paolo Lissoni; Antonio Ardizzoia; Maristella Perego; M G Grassi; M Arosio; P D'Amico; M Cazzaniga; S Crispino; Gabriele Tancini; S Barni
Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha.
Journal of biological regulators and homeostatic agents 1993;7(2):73-5.
1993: Paolo Lissoni; S Pittalis; Fernando Brivio; E Tisi; Franco Rovelli; Antonio Ardizzoia; S Barni; Gabriele Tancini; G Giudici; A Biondi
In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2.
Cancer 1993;71(6):2076-81.
1993: S Barni; C Archili; Paolo Lissoni; F Paolorossi; S Crispino; Gabriele Tancini
A weekly schedule of epirubicin in pretreated advanced breast cancer.
Tumori 1993;79(1):45-8.
1993: Paolo Lissoni; S Barni; Franco Rovelli; Fernando Brivio; Antonio Ardizzoia; Gabriele Tancini; A Conti; G J Maestroni
Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
European journal of cancer (Oxford, England : 1990) 1993;29A(2):185-9.
1993: Paolo Lissoni; S Barni; E Tisi; Franco Rovelli; S Pittalis; R Rescaldani; L Vigoré; A Biondi; Antonio Ardizzoia; Gabriele Tancini
In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer.
European journal of cancer (Oxford, England : 1990) 1993;29A(8):1127-32.
1993: Paolo Lissoni; Antonio Ardizzoia; E Tisi; F Rossini; S Barni; Gabriele Tancini; A Conti; G J Maestroni
Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
Journal of biological regulators and homeostatic agents 1993;7(1):34-6.
1993: Paolo Lissoni; M Cazzaniga; Antonio Ardizzoia; F Rossini; G Fiorelli; Gabriele Tancini; S Pittalis; S Barni
Cytokine regulation of iron metabolism: effect of low-dose interleukin-2 subcutaneous therapy on ferritin, transferrin and iron blood concentrations in cancer patients.
Journal of biological regulators and homeostatic agents 1993;7(1):31-3.
1993: Fernando Brivio; Paolo Lissoni; S Barni; Gabriele Tancini; A Ardizzoia; L Erba; G Alderi; V Nociti
Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study.
The European journal of surgery = Acta chirurgica 1993;159(1):43-7.
1992: S Barni; Paolo Lissoni; M Cazzaniga; Antonio Ardizzoia; F Paolorossi; Fernando Brivio; M Perego; Gabriele Tancini; A Conti; G Maestroni
Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma.
Tumori 1992;78(6):383-7.
1992: Paolo Lissoni; Franco Rovelli; S Barni; Antonio Ardizzoia; S Pittalis; E Tisi; V Perlangeli; Gabriele Tancini
Modulation of macrophage response to interleukin-2 immunotherapy by interleukin-3 in cancer patients.
Biological chemistry Hoppe-Seyler 1992;373(12):1217-22.
1992: Paolo Lissoni; Antonio Ardizzoia; Franco Rovelli; M Perego; P Cardellini; Gabriele Tancini; S Barni
Effect of interferon-alpha on soluble interleukin-2 receptor and tumor necrosis factor increase during immunotherapy with interleukin-2.
The International journal of biological markers 1992;7(4):268-9.
1992: Paolo Lissoni; Franco Rovelli; E Tisi; D Ballabio; C Benenti; Antonio Ardizzoia; S Barni; B Tancini
Effects of interleukin-2 immunotherapy on soluble lymphocyte markers in cancer patients.
The International journal of biological markers 1992;7(4):260-2.
1992: Paolo Lissoni; Franco Rovelli; E Tisi; Antonio Ardizzoia; V Perlangeli; S Barni; Gabriele Tancini
Endocrine effects of human recombinant interleukin-3 in cancer patients.
The International journal of biological markers 1992;7(4):230-3.
1992: S Crispino; Paolo Lissoni; Antonio Ardizzoia; S Barni; Franco Rovelli; Gabriele Tancini
Effects of granulocyte-macrophage colony stimulating factor on cortisol, growth hormone, prolactin and melatonin in cancer patients (short communication).
Journal of biological regulators and homeostatic agents 1992;6(4):142-4.
1992: Paolo Lissoni; S Barni; Antonio Ardizzoia; Fernando Brivio; Gabriele Tancini; A Conti; G J Maestroni
Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
Journal of biological regulators and homeostatic agents 1992;6(4):132-6.
1992: Paolo Lissoni; F Pelizzoni; O Mauri; M Perego; S Pittalis; S Barni
Enhanced secretion of tumour necrosis factor in patients with myocardial infarction.
The European journal of medicine 1992;1(5):277-80.
1992: Antonio Ardizzoia; Paolo Lissoni; Fernando Brivio; E Tisi; Maristella Perego; M G Grassi; S Pittalis; S Crispino; S Barni; Gabriele Tancini
Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease.
Journal of biological regulators and homeostatic agents 1992;6(3):103-7.
1992: Paolo Lissoni; E Tisi; S Barni; Antonio Ardizzoia; Franco Rovelli; R Rescaldani; D Ballabio; C Benenti; M Angeli; Gabriele Tancini
Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
British journal of cancer 1992;66(1):155-8.
1992: E Tisi; Paolo Lissoni; M Angeli; C Arrigoni; E Corno; E Cassina; D Ballabio; C Benenti; S Barni; Gabriele Tancini
Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma.
Cancer 1992;69(10):2458-62.
1992: Paolo Lissoni; S Barni; Antonio Ardizzoia; F Paolorossi; E Tisi; S Crispino; Gabriele Tancini
Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions.
Tumori 1992;78(2):118-20.
1992: E Tisi; E Cassina; D Ballabio; C Benenti; M Perego; S Barni; Gabriele Tancini; Paolo Lissoni
Blood levels of atrial natriuretic peptide in non-small cell lung cancer and their changes with surgery.
The International journal of biological markers 1992;7(2):121-2.
1992: Paolo Lissoni; S Barni; Antonio Ardizzoia; S Crispino; F Paolorossi; C Archili; M Vaghi; Gabriele Tancini
Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha.
European journal of cancer (Oxford, England : 1990) 1992;28(1):92-6.
1992: Fernando Brivio; Paolo Lissoni; E Tisi; L Erba; S Barni; Gabriele Tancini; R Rescaldani; G Alderi; V Nociti
Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patients.
Oncology 1992;49(3):215-8.
1992: Paolo Lissoni; S Barni; Antonio Ardizzoia; F Paolorossi; S Crispino; Gabriele Tancini; E Tisi; C Archili; D De Toma; G Pipino
Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.
Oncology 1992;49(5):336-9.
1991: Paolo Lissoni; Fernando Brivio; S Pittalis; Maristella Perego; Antonio Ardizzoia; O Mauri; S Barni; S Crispino; Gabriele Tancini
Decrease in cholesterol levels during the immunotherapy of cancer with interleukin-2.
British journal of cancer 1991;64(5):956-8.
1991: Paolo Lissoni; S Barni; O Mauri; F Pelizzoni; S Pittalis; G Osculati; Franco Valagussa
[Cardioangioimmunology: the immune implications in the principle cardiovascular pathologies].
Giornale italiano di cardiologia 1991;21(10):1139-46.
1991: S Barni; Paolo Lissoni; F Paolorossi; R Rescaldani; S Crispino; C Archili; G Cattaneo; Gabriele Tancini
Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical response.
Tumori 1991;77(3):227-31.
1991: Paolo Lissoni; S Barni; Franco Rovelli; S Crispino; Gabriele Fumagalli; S Pescia; M Vaghi; G Camesasca; Gabriele Tancini
Neuroendocrine effects of subcutaneous interleukin-2 injection in cancer patients.
Tumori 1991;77(3):212-5.
1991: S Barni; Paolo Lissoni; D Mandelli; C Archili; G Real; A L Sormani; R Caprotti; Gabriele Tancini
Relation between surgery-induced prolactin increase and the menstrual cycle phase at time of surgery in premenopausal breast cancer.
The International journal of biological markers 1991;6(2):103-6.
1991: Fernando Brivio; Paolo Lissoni; D Mancini; E Tisi; Gabriele Tancini; S Barni; V Nociti
Effect of antitumor surgery on soluble interleukin-2 receptor serum levels.
American journal of surgery 1991;161(4):466-9.
1991: E Tisi; Paolo Lissoni; Franco Rovelli; D Mandelli; S Barni; Gabriele Tancini
Blood levels of IGF-I in non-small cell lung cancer: relation to clinical data.
The International journal of biological markers 1991;6(2):99-102.
1991: Paolo Lissoni; S Barni; Franco Rovelli; Gabriele Tancini
Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary report.
Oncology 1991;48(2):125-7.
1991: Paolo Lissoni; E Tisi; Fernando Brivio; S Barni; Franco Rovelli; M Perego; Gabriele Tancini
Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
European journal of cancer (Oxford, England : 1990) 1991;27(8):1014-6.
1991: Paolo Lissoni; S Barni; G Cattaneo; Gabriele Tancini; G Esposti; D Esposti; Franco Fraschini
Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies.
Oncology 1991;48(6):448-50.
1990: Paolo Lissoni; S Barni; G Cattaneo; C Archili; M Perego; Gabriele Tancini
Evaluation of the cardiovascular toxicity related to cancer immunotherapy with interleukin-2 by monitoring atrial natriuretic peptide secretion: a case report.
Tumori 1990;76(6):603-5.
1990: Paolo Lissoni; Fernando Brivio; S Barni; Gabriele Tancini; G Cattaneo; C Archili; A Conti; G J Maestroni
Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
Anticancer research 1990;10(6):1759-61.
1990: Antonio Colombo; S Crispino; Gabriele Tancini; A Personeni; R Taino; E Sarti; S Barni; Paolo Lissoni; F Placa; P Mazzola
[Radiotherapy plus a combination of cisplatin and 5-fluorouracil for locally advanced head and neck neoplasms. Study of feasibility and preliminary results].
La Radiologia medica 1990;80(5):713-8.
1990: Paolo Lissoni; Gabriele Tancini; Franco Rovelli; G Cattaneo; C Archili; S Barni
Serum interleukin-2 levels in relation to the neuroendocrine status in cancer patients.
British journal of cancer 1990;62(5):838-9.
1990: Paolo Lissoni; S Barni; G Cattaneo; C Archili; S Crispino; Gabriele Tancini; L D'Angelo; S Magni; G Fiorelli
Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome.
The International journal of biological markers 1990;5(4):195-7.
1990: Paolo Lissoni; M A Galli; S Barni; V Colombo; F Pelizzoni; R Fumagalli; Gabriele Tancini
[The cardiovascular toxicity of interleukin-2: the pathogenic mechanisms and treatment].
Giornale italiano di cardiologia 1990;20(7):631-5.
1990: Paolo Lissoni; S Barni; C Archili; G Cattaneo; Franco Rovelli; A Conti; G J Maestroni; Gabriele Tancini
Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer.
Anticancer research 1990;10(3):753-7.
1990: S Barni; Paolo Lissoni; F Paolorossi; S Crispino; C Archili; Gabriele Tancini
A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates.
Tumori 1990;76(1):58-60.
1990: Paolo Lissoni; S Barni; Franco Rovelli; R Rescaldani; V Rizzo; A Biondi; Gabriele Tancini
Correlation of serum interleukin-2 levels, soluble interleukin-2 receptors and T lymphocyte subsets in cancer patients.
Tumori 1990;76(1):14-7.
1990: Paolo Lissoni; E Mainini; C Mazzi; G Cattaneo; S Barni
A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia.
Journal of endocrinological investigation 1990;13(2):85-9.
1990: Paolo Lissoni; S Crispino; S Barni; A Sormani; Fernando Brivio; F Pelizzoni; A Brenna; G Bratina; Gabriele Tancini
Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer.
Oncology 1990;47(3):275-7.
1990: C Archili; Paolo Lissoni; G Cattaneo; Franco Rovelli; Fernando Brivio; Gabriele Tancini; S Barni
Lack of changes in soluble interleukin-2 receptor serum levels during chemotherapy-induced lymphocyte damage.
The International journal of biological markers 1990;5(1):43-5.
1990: Paolo Lissoni; A L Sormani; Gabriele Tancini; G Cattaneo; C Archili; D Mandelli; S Crispino; F Paolorossi; S Barni
Postoperative hyperprolactinaemia and early recurrence rate in breast cancer.
European journal of cancer (Oxford, England : 1990) 1990;26(9):953-6.
1990: Gabriele Tancini; S Barni; R Rescaldani; G Fiorelli; S Vivani; Paolo Lissoni
Analysis of T helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms.
Oncology 1990;47(5):381-4.
1990: Paolo Lissoni; Gabriele Tancini; C Archili; R Rescaldani; G Cattaneo; S Crispino; S Barni
Changes in T lymphocyte subsets after single dose epirubicin.
European journal of cancer (Oxford, England : 1990) 1990;26(6):767-8.
1990: Paolo Lissoni; S Barni; Franco Rovelli; Simonetta Viviani; G J Maestroni; A Conti; Gabriele Tancini
The biological significance of soluble interleukin-2 receptors in solid tumors.
European journal of cancer (Oxford, England : 1990) 1990;26(1):33-6.
1989: S Crispino; A Brenna; D Colombo; B Flores; S D'Amico; Paolo Lissoni; S Barni; F Paolorossi; G Bratina; Gabriele Tancini
Ki-67 labeling index in breast cancer.
Tumori 1989;75(6):557-62.
1989: S Crispino; Gabriele Tancini; S Barni; Paolo Lissoni
Evidence for altered hypothalamic-hypophyseal-gonadal axis in untreated patients with testicular germ-cell tumor.
Tumori 1989;75(5):505-9.
1989: Paolo Lissoni; S Barni; R Rescaldani; Franco Rovelli; Gabriele Tancini
Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumours.
British journal of cancer 1989;60(4):616-7.
1989: Paolo Lissoni; Simonetta Viviani; A Santoro; S Barni; Gabriele Tancini
Serum levels of interleukin-2 in cancer patients: preliminary considerations.
The International journal of biological markers 1989;4(4):203-6.
1989: Paolo Lissoni; Gabriele Tancini; S Barni; Simonetta Viviani; C Archili; G Cattaneo; G Fiorelli
Alterations of pineal gland and of T lymphocyte subsets in metastatic cancer patients: preliminary results.
Journal of biological regulators and homeostatic agents 1989;3(4):181-3.
1989: Paolo Lissoni; V Rizzo; S Barni; R Rescaldani; Franco Rovelli; A Biondi; C Archili; F Frigerio; Gabriele Tancini
Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlated.
The International journal of biological markers 1989;4(3):170-3.
1989: S Barni; Paolo Lissoni; A Sormani; F Pelizzoni; Fernando Brivio; S Crispino; Gabriele Tancini
The pineal gland and breast cancer: serum levels of melatonin in patients with mammary tumors and their relation to clinical characteristics.
The International journal of biological markers 1989;4(3):157-62.
1989: Paolo Lissoni; S Barni; Gabriele Tancini; Simonetta Viviani; Franco Rovelli; R Rescaldani; G Fiorelli
Effects of cancer chemotherapy on the relation between serum levels of soluble interleukin-2 receptors and CD4/CD8 ratio in patients with solid neoplasms.
Journal of biological regulators and homeostatic agents 1989;3(3):131-3.
1989: M Tagliabue; Paolo Lissoni; S Barni; I Macchi; Gabriele Tancini; S Crispino; L Ferri; E Salvini
A radiologic study by CT scan of pineal size in cancer patients: correlation to melatonin blood levels.
Tumori 1989;75(3):226-8.
1989: Paolo Lissoni; S Barni; S Crispino; Gabriele Tancini; F Fraschini
Endocrine and immune effects of melatonin therapy in metastatic cancer patients.
European journal of cancer & clinical oncology 1989;25(5):789-95.
1989: Gabriele Tancini; S Barni; S Crispino; F Paolorossi; Paolo Lissoni
A study of thyroid function in cancer cachexia.
Tumori 1989;75(2):185-8.
1989: S Crispino; G Lombardi; G Bratina; Paolo Lissoni; S Barni; Gabriele Tancini
Malignant testicular germ cell tumor in father and son: a case report.
Tumori 1989;75(2):177-80.
1989: Gabriele Tancini; Paolo Lissoni; S Barni; R Rescaldani; Franco Rovelli; A Sormani; S Crispino; T Saporito; E Tisi; C Benenti
Serum levels of soluble interleukin-2 receptors and their relation to CD4/CD8 ratio in patients with advanced solid tumors.
The International journal of biological markers 1989;4(2):123-4.
1989: Paolo Lissoni; S Barni; F Garuti; R Astuti; Gabriele Tancini
Opioid receptors in human neoplasms: growth hormone and prolactin response to morphine, met-enkephalin and buprenorphine in cancer patients.
The International journal of biological markers 1989;4(1):55-6.
1989: Paolo Lissoni; S Crispino; S Barni; Gabriele Tancini
Prolactin secretion in testicular cancer patients.
The International journal of biological markers 1989;4(1):27-30.
1988: Franco Rovelli; Paolo Lissoni; S Crispino; S Barni; G Fumagalli; F Paolorossi; Gabriele Tancini
Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study.
Tumori 1988;74(6):633-7.
1988: D Esposti; Paolo Lissoni; Gabriele Tancini; S Barni; S Crispino; F Paolorossi; Franco Rovelli; L Ferri; G Cattaneo; G Esposti
A study on the relationship between the pineal gland and the opioid system in patients with cancer. Preliminary considerations.
Cancer 1988;62(3):494-9.
1988: S Barni; Paolo Lissoni; S Crispino; Franco Rovelli; G Esposti; Franco Fraschini; Gabriele Tancini
Serum levels of melatonin in cancer patients and their relation to body sizes.
The International journal of biological markers 1988;3(3):193-6.
1988: Paolo Lissoni; Gabriele Tancini; S Barni; S Crispino; F Paolorossi; Franco Rovelli; G Cattaneo; Franco Fraschini
Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patients.
Tumori 1988;74(3):339-45.
1988: S Barni; Paolo Lissoni; Franco Rovelli; S Crispino; F Paolorossi; D Esposti; G Esposti; Franco Fraschini; Gabriele Tancini
Alteration of opioid peptide circadian rhythm in cancer patients.
Tumori 1988;74(3):357-60.
1988: Paolo Lissoni; S Barni; S Crispino; G Cattaneo; Gabriele Tancini
Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancer.
Tumori 1988;74(3):303-8.
1988: S Barni; Paolo Lissoni; S Crispino; G Cattaneo; Franco Rovelli; G Fumagalli; Gabriele Tancini
Neuroimmunomodulation in cancer patients: correlations between melatonin and beta-endorphin blood levels and T helper/suppressor ratio.
The International journal of biological markers 1988;3(2):82-6.
1988: Paolo Lissoni; S Barni; Gabriele Tancini; S Crispino; F Paolorossi; G Cattaneo; Valeria Lucini; M Mariani; D Esposti; G Esposti
Relation between lymphocyte subpopulations and pineal function in patients with early or metastatic cancer.
Annals of the New York Academy of Sciences 1988;521():290-9.
1987: Paolo Lissoni; S Barni; F Paolorossi; S Crispino; Franco Rovelli; L Ferri; G Delitala; Gabriele Tancini
Evidence for altered opioid activity in patients with cancer.
British journal of cancer 1987;56(6):834-7.
1987: Paolo Lissoni; S Barni; Gabriele Tancini; S Crispino; F Paolorossi; Valeria Lucini; M Mariani; G Cattaneo; D Esposti; G Esposti
Clinical study of melatonin in untreatable advanced cancer patients.
Tumori 1987;73(5):475-80.
1987: Antonio Colombo; S Crispino; S Barni; F Paolorossi; F Frigerio; Gabriele Tancini; Paolo Lissoni; F Placa; P Mazzola; S Nava
[Concomitant therapy with cisplatin and radiotherapy in locally advanced tumors of the cervico-facial area].
La Radiologia medica 1987;74(4):334-7.
1987: S Barni; F Frigerio; Paolo Lissoni; S Crispino; F Paolorossi
Anal squamous cell carcinoma arising on radio-dermatitis cured with chemotherapy alone: case report.
Tumori 1987;73(4):423-4.
1987: S Barni; Paolo Lissoni; F Paolorossi; S Crispino; Franco Rovelli; L Ferri; A Sormani; U D'Alonso; A Bugatti; V Nociti
Effects of radical mastectomy on prolactin blood levels in patients with breast cancer.
European journal of cancer & clinical oncology 1987;23(8):1141-5.
1987: Paolo Lissoni; F Paolorossi; S Barni; Gabriele Tancini; S Crispino; Franco Rovelli; L Ferri; G Esposti; D Esposti; Franco Fraschini
Correlation between changes in prolactin and melatonin serum levels after radical mastectomy.
Tumori 1987;73(3):263-7.
1987: Paolo Lissoni; S Barni; S Crispino; Gabriele Tancini; F Paolorossi; L Ferri; G Delitala
Synthetic enkephalin analog in the treatment of cancer chemotherapy-induced vomiting.
Cancer treatment reports 1987;71(6):665-6.
1987: S Barni; Paolo Lissoni; Gabriele Tancini; S Crispino; F Paolorossi; Franco Rovelli; G Fumagalli; L Ferri; D Esposti; G Esposti
Acute effects of various chemotherapeutic combinations on hypophyseal and pineal hormone secretions in cancer patients.
Tumori 1987;73(2):181-5.
1986: S Barni; Paolo Lissoni; Gabriele Tancini; S Crispino; F Paolorossi; Franco Rovelli; G Fumagalli; L Ferri
Prolactin response to thyrotropin-releasing hormone in early and advanced human breast cancer.
Tumori 1986;72(4):399-403.